ChemicalBook > CAS DataBase List > Narmafotinib

Narmafotinib

Product Name: Narmafotinib
CAS No.: 1393653-34-3
Chemical Name: Narmafotinib
Synonyms: AMP-945;CTx-0294945;Narmafotinib;Unii-16T7U12J7U;AMP-945, 10 mM in DMSO;Focal adhesion kinase,Inhibitor,PTK2 protein tyrosine kinase 2,inhibit,AMP945,PTK2,AMP-945,AMP 945,FAK;2-(2-(2-(2-((2-Methoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)phenyl)acetamide;Benzeneacetamide, 2-[2-[2-[[2-methoxy-4-(1-methyl-4-piperidinyl)phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]ethyl]-
CBNumber: CB78246546
Molecular Formula: C28H32F3N5O2
Formula Weight: 527.58
MOL File: 1393653-34-3.mol

Less

Narmafotinib Property

Boiling point:: 658.2±65.0 °C(Predicted)
Density: 1.259±0.06 g/cm3(Predicted)
storage temp.: 4°C, protect from light
pka: 16.18±0.40(Predicted)
form: Solid
color: White to light yellow

Less

Hazard and Precautionary Statements (GHS)

Less

Narmafotinib Chemical Properties,Usage,Production

Description

NARMAFOTINIB is a small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.

Uses

Narmafotinib (AMP-945) is an orally active inhibitor of the enzyme focal adhesion kinase (FAK, KD=0.21 nM). Narmafotinib inhibits autophosphorylation of 397Y-FAK in MDA-MB-231 cells with an IC50=7 nM and exhibits low general cellular toxicity (IC50=2.7 μM, MDA-MB-231 cells). Narmafotinib can be used for anti-cancer study[1].

Biological Activity

in vivo

Narmafotinib (80 mg/kg; p.o.; daily for 28 days) combined with Bevacizumab (HY-P9906) prevents tumor progression and enhances the durability of response in MDA-MB-231 xenograft mice model^[1].

Animal Model:	Mice were injected orthotopically with MDA-MB-231 cells^[1]
Dosage:	80 mg/kg
Administration:	Oral gavage (p.o.); daily for 28 days
Result:	Tumor growth was significantly inhibited (88% TGI) in combination with Bevacizumab (HY-P9906) after 28 days. When the Bevacizumab treatment group tumor size reached ethical end point (1000 mm³), the average size of the tumors in the combination group was still only 562 mm³.

References

[1] I. STREET. Abstract LB-308: Combination of CTx-0294945 a highly selective inhibitor of focal adhesion kinase with bevacizumab in pre-clinical models of breast cancer[J]. Cancer research, 2012, 11 1. DOI:10.1158/1538-7445.AM2012-LB-308.
[2] JOHN LAMBERT. Abstract CT511: A phase 1 trial of AMP945, a potent and selective focal adhesion kinase inhibitor, in healthy volunteers[J]. Cancer research, 2022. DOI:10.1158/1538-7445.am2022-ct511.
[3] COCK T A, BISHOP A, KRUGER N, et al. Abstract CT220: Phase 1b/2a of narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel (Abraxane) standard of care as first-line therapy in patients with advanced pancreatic cancer (ACCENT trial): interim analysis[J]. ACS Chemical Health & Safety, 2024, 6 3. DOI:10.1158/1538-7445.am2024-ct220.
[4] C. BURNS. The effect of adding a selective FAK inhibitor AMP945 to FOLFIRINOX in a model of pancreatic cancer.[J]. Journal of Clinical Oncology, 2023. DOI:10.1200/jco.2023.41.16\_suppl.e15128.

Narmafotinib Preparation Products And Raw materials

Raw materials

Preparation Products

Less

Narmafotinib Suppliers

China 30 United States 3 Global 33

ShangHai Biochempartner Co.,Ltd

Tel: 177-54423994 17754423994
Fax: QQ:2853530913
Email: 2853530910@QQ.com
Country: China
ProdList: 8000
Advantage: 62

Shanghai Chaolan Chemical Technology Center

Tel: 021-QQ：65489617 15618227136
Fax: 21-5161 9052
Email: Sales@ATKchemical.com
Country: China
ProdList: 9119
Advantage: 58

Fujian boshi pharmaceutical technology co. LTD

Tel: 0595-22008920; 18120708884
Email: 393612455@qq.com
Country: China
ProdList: 255
Advantage: 58

Suzhou Chenrui Biotechnology Co. LTD

Tel: 17625585511
Fax: qq：1580084073
Email: 1580084073@qq.com
Country: China
ProdList: 959
Advantage: 58

Chunchuang (Wuhan) Technology Co., Ltd

Tel: 15727060112
Email: yutianchun2007@126.com
Country: China
ProdList: 9814
Advantage: 58

Hangzhou Taorui Biotechnology Co., Ltd

Tel: 4000-360-990 15268198094
Email: sales@torreybio.com
Country: China
ProdList: 3804
Advantage: 58

Hebei Weite Medical Technology Co., Ltd

Tel: 13180081292 13180081292
Email: contact@wetogethermed.com
Country: China
ProdList: 7947
Advantage: 58

Zhengzhou convergence chemical co., LTD

Tel: 0371-0371-55153829 18003835034
Email: 2853979819@qq.com
Country: China
ProdList: 9998
Advantage: 58

Hubei wei shi reagent group ltd., company

Tel: 027-59102966 18717199209
Fax: 027-59379337
Email: 2853877583@qq.com
Country: China
ProdList: 2716
Advantage: 58

Bide Pharmatech Ltd.

Tel: 400-1647117 13681763483
Email: product02@bidepharm.com
Country: China
ProdList: 62220
Advantage: 58

TargetMol Chemicals Inc.

Tel: 4008200310
Email: marketing@tsbiochem.com
Country: China
ProdList: 24961
Advantage: 58

Wuhan Jingkangen Biomedical Technology Co., Ltd

Tel: 13720134139 086-15871494362 13720134139
Email: orders@jknbiochem.com
Country: China
ProdList: 6614
Advantage: 58

Nantong QuanYi Biotechnology Co., Ltd

Tel: 0513-66337626 18051384581
Email: sales@chemhifuture.com
Country: China
ProdList: 5929
Advantage: 58

Shanghai Easy CDMO Co.,Ltd

Tel: 021-61734564 13854185395;
Email: info@easycdmo.com
Country: China
ProdList: 10024
Advantage: 58

https://hanhongsci.com/

Tel: 021-54306202 18917919676
Email: info@hanhongsci.com
Country: China
ProdList: 29995
Advantage: 58

Suzhou Meidi Senuo Pharmaceutical Technology Co., Ltd.

Tel: 13771642864
Fax: 1078336263
Email: snhuyu_2008@126.com
Country: China
ProdList: 1165
Advantage: 58

Nanjing Shizhou Biology Technology Co.,Ltd

Tel: 025-85560043 15850508050
Fax: 025-85563444
Email: cindy.huang@synzest.com
Country: China
ProdList: 12000
Advantage: 58

Shanghai jerryxing Biomedical Technology Co., Ltd

Tel: 17721492509; 17721492509
Email: 643638326@qq.com
Country: China
ProdList: 4976
Advantage: 58

Changsha Fuzhen Biotechnology Co.，LTD

Tel: 0731-13823398 15111215862
Email: 313359644@qq.com
Country: China
ProdList: 4161
Advantage: 58

RD International Technology Co., Limited

Tel: 18024082417
Email: market@ubiochem.com
Country: China
ProdList: 9835
Advantage: 58

Olix (Shanghai) Pharmaceutical Technology Co., Ltd

Tel: 17316404525 17316404525
Email: 209533805@qq.com
Country: China
ProdList: 9767
Advantage: 58

Jiangsu Aikon Biopharmaceutical R&D Co.,Ltd

Tel: 025-58851090 17714375163
Email: 2881759498@qq.com
Country: China
ProdList: 13011
Advantage: 58

Chengdu Peter-like Biotechnology Co., Ltd.

Tel: 028-81700200 13308200041
Email: 2851167782@qq.com
Country: China
ProdList: 11146
Advantage: 58

Sangon Biotech (Shanghai) Co.,Ltd.

Tel: 400-821-026
Email: Sales@sangon.com
Country: China
ProdList: 6710
Advantage: 58

Changzhou Xianglong Pharmaceutical Technology Co., Ltd.,

Tel: 18915873328 18915873328
Email: 296197970@qq.com
Country: China
ProdList: 11051
Advantage: 58

Selleck Chemicals

Tel: 400-668-6834
Email: info@selleck.cn
Country: China
ProdList: 6071
Advantage: 58

ATK CHEMICAL COMPANY LIMITED

Tel: +undefined-21-51877795
Fax: +86 21 5161 9052/ 5187 7796
Email: ivan@atkchemical.com
Country: China
ProdList: 33024
Advantage: 60

Wuhan Jingkang en Biomedical Technology Co., Ltd

Tel: +8613720134139
Email: orders@jknbiochem.com
Country: China
ProdList: 5221
Advantage: 58

Absin Bioscience Inc.

Tel: --
Fax: --
Email: chenjw@absin.cn
Country: CHINA
ProdList: 6208
Advantage: 58

Proteintech China

Tel: --
Fax: --
Email: Proteintech-CN@ptglab.com
Country: CHINA
ProdList: 6290
Advantage: 58

1393653-34-3, NarmafotinibRelated Search:

Conteltinib APG-2449 Repaglinide Captopril Defactinib Conteltinib (CT-707) Ifebemtinib Esuberaprost Sodium

Benzeneacetamide, 2-[2-[2-[[2-methoxy-4-(1-methyl-4-piperidinyl)phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]ethyl]-

AMP-945

Focal adhesion kinase,Inhibitor,PTK2 protein tyrosine kinase 2,inhibit,AMP945,PTK2,AMP-945,AMP 945,FAK

Unii-16T7U12J7U

Narmafotinib

2-(2-(2-(2-((2-Methoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)phenyl)acetamide

AMP-945, 10 mM in DMSO

CTx-0294945

1393653-34-3

C28H32F3N5O2